A previous clinical trial of patients with metastatic melanoma evaluated the treatment regimen of bevacizumab in combination with escalating doses of IFN-α-2b (5 MU/m2 for 2 weeks and then 10 MU/m2 thereafter) [37]. This evidence concerns the gene IFNA2 and metastatic melanoma.